Theravance Biopharma, Inc. - Ordinary Shares (TBPH)
TBPH moved a median of +0.10% 30 minutes after news, and +0.42% by the close. How TBPH actually reacts to news — the realized, point-in-time move the market made, measured across 326 labeled events over the last three years with zero look-ahead.
TBPH’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.03% | 51% | 324 |
| 30-min | +0.10% | 57% | 325 |
| 60-min | +0.03% | 51% | 325 |
| to close | +0.42% | 59% | 322 |
| Middle 50% of TBPH reactions | -0.46% to +0.88% |
|---|---|
| Median reaction (30-min) | +0.10% |
| Measured reactions | 326 |
Half of all Theravance Biopharma, Inc. - Ordinary Shares news events land between -0.46% and +0.88% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How TBPH reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 16 | -0.13% | 44% | +0.14% |
| Analyst downgrades | 35 | +0.03% | 54% | -0.06% |
| Coverage initiations | 12 | 0.00% | 33% | +0.63% |
| Rating reiterations | 27 | +0.20% | 67% | +0.40% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how TBPH ranks against every other measured name →
That’s how TBPH usually reacts — get an email when it moves on news →Email me when TBPH moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to TBPH's baseline. Nothing else.
Recent TBPH events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 15-12G Theravance Biopharma, | SEC filing · Form 15-12G | SEC EDGAR | — | — | |
| Form S-8 POS Theravance Biopharma, | SEC filing · Form S-8 | SEC EDGAR | — | — | |
| Form 8-K Theravance Biopharma, For: Sep 23 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 8-K Theravance Biopharma, For: Sep 18 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.12% | |
| Form 8-K Theravance Biopharma, For: Sep 10 | SEC filing · Form 8-K | SEC EDGAR | -0.29% | -0.18% | |
| Form 8-K Theravance Biopharma, For: Aug 25 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.12% | |
| Form DEFA14A Theravance Biopharma, | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | -0.12% | |
| Form DEFM14A Theravance Biopharma, | SEC filing · Form DEFM14A | SEC EDGAR | +0.06% | +0.24% | |
| TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders | Press release | Business Wire | -0.06% | -0.29% | |
| Form 10-Q Theravance Biopharma, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +0.06% | |
| Form PREM14A Theravance Biopharma, For: Aug 11 | SEC filing · Form PREM14A | SEC EDGAR | +0.00% | +0.06% | |
| Form 8-K Theravance Biopharma, For: Aug 10 | SEC filing · Form 8-K | SEC EDGAR | +0.06% | — | |
| Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Press release | PR Newswire | +0.06% | — | |
| Are TBPH, IRDM, LCII, PATK Obtaining Fair Deals for their Shareholders? | Press release | PR Newswire | -0.12% | -0.41% | |
| Form 8-K Theravance Biopharma, For: Jun 28 | SEC filing · Form 8-K | SEC EDGAR | +0.06% | +0.53% | |
| Form DEFA14A Theravance Biopharma, | SEC filing · Form DEFA14A | SEC EDGAR | +0.06% | +0.53% | |
| TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders | Press release | Business Wire | -0.03% | -0.84% | |
| THERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHT | Press release | PR Newswire | +0.06% | +0.53% | |
| Form 8-K Theravance Biopharma, For: Jun 19 | SEC filing · Form 8-K | SEC EDGAR | +0.64% | +1.17% | |
| Form 8-K Theravance Biopharma, For: Jun 12 | SEC filing · Form 8-K | SEC EDGAR | -0.75% | -1.75% | |
| Form 10-Q Theravance Biopharma, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.33% | +0.47% | |
| Form 8-K Theravance Biopharma, For: May 07 | SEC filing · Form 8-K | SEC EDGAR | +0.33% | +0.47% | |
| Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update | Press release | PR Newswire | +0.33% | +0.47% | |
| Form DEF 14A Theravance Biopharma, For: Jun 12 | SEC filing · Form DEF | SEC EDGAR | -0.27% | +0.54% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Theravance Biopharma, Inc. (TBPH) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | -0.36% | +0.12% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Theravance Biopharma, Inc. (TBPH) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | -0.30% | -1.31% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Theravance Biopharma, Inc. (TBPH) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.18% | -2.11% | |
| Theravance Biopharma, Inc. (TBPH) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.00% | +1.95% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Theravance Biopharma, Inc. (TBPH) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.06% | +1.06% | |
| Theravance Biopharma, Inc. (TBPH) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.43% | +0.43% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Theravance Biopharma, Inc. (TBPH) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | +0.15% | +0.49% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Theravance Biopharma, Inc. (TBPH) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | +0.52% | +0.24% | |
| Theravance Biopharma, Inc. (TBPH) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.09% | +0.76% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Theravance Biopharma, Inc. (TBPH) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.24% | -0.54% | |
| Form 8-K Theravance Biopharma, For: Mar 27 | SEC filing · Form 8-K | SEC EDGAR | +0.65% | +5.39% | |
| Form 10-K Theravance Biopharma, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.03% | +0.14% | |
| Form 8-K Theravance Biopharma, For: Mar 19 | SEC filing · Form 8-K | SEC EDGAR | +0.64% | +2.86% | |
| Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | Press release | PR Newswire | +0.64% | +2.86% | |
| Form 8-K Theravance Biopharma, For: Mar 03 | SEC filing · Form 8-K | SEC EDGAR | -4.31% | -0.50% | |
| Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions | Press release | PR Newswire | -4.31% | -0.50% | |
| Form 8-K Theravance Biopharma, For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | -1.05% | +3.31% | |
| Form 8-K Theravance Biopharma, For: Dec 08 | SEC filing · Form 8-K | SEC EDGAR | -0.54% | -3.10% | |
| Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025 | Press release | PR Newswire | +0.78% | -0.56% | |
| Theravance Biopharma to Participate in Upcoming Investor Conferences | Press release | PR Newswire | -0.68% | -3.90% | |
| Form 10-Q Theravance Biopharma, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.69% | — | |
| Form 8-K Theravance Biopharma, For: Nov 10 | SEC filing · Form 8-K | SEC EDGAR | +10.02% | +18.82% | |
| Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Press release | PR Newswire | +10.02% | +18.82% | |
| Theravance Biopharma to Present Data on Ampreloxetine at the 36th International Symposium on The Autonomic Nervous System | Press release | PR Newswire | +0.00% | +0.71% | |
| Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025 | Press release | PR Newswire | +0.35% | -0.35% | |
| Theravance Biopharma Launches Disease Education Campaign to Advance Scientific Understanding of Neurogenic Orthostatic Hypotension Due to Multiple System Atrophy | Press release | Business Wire | -0.64% | +0.36% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the TBPH section they belong to.
Where else TBPH is measured.
TBPH earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| DBV Technologies S.A. - American Depositary Shares (DBVT) | 327 | -0.15% | 40% |
| Novartis AG (NVS) | 326 | +0.03% | 51% |
| Verona Pharma plc - American Depositary Shares (VRNA) | 325 | -0.03% | 39% |
| Bionano Genomics, Inc. (BNGO) | 321 | -0.94% | 31% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Theravance Biopharma, Inc. - Ordinary Shares's median reaction calculated?
Every labeled TBPH news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 326 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 57% of TBPH's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does TBPH's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.